MINI LONG - NOVO-NORDISK B | Market Closed - Börse Stuttgart 02:57:57 2024-07-16 pm EDT | ||
| 14.45 EUR | +0.07% |
|
| Current month | -5.56% | ||
| 1 month | -4.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 14.45 | +0.07% |
| 24-07-15 | 14.44 | -1.23% |
| 24-07-12 | 14.62 | +3.39% |
| 24-07-11 | 14.14 | -4.59% |
| 24-07-10 | 14.82 | +2.63% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 02:57 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MD9XZ7 |
| ISIN | DE000MD9XZ72 |
| Date issued | 2022-10-27 |
| Strike | 430.8 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.01 € |
|---|---|
| Lowest since issue | 0.32 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Certificates
- Certificat
